[ad_1]
MANCHESTER, England – (COMMERCIAL THREAD) – To mark World Psoriasis Day (October 29e), AxisBiotix-Ps â„¢, a probiotic dietary supplement aimed at relieving symptoms associated with psoriasis, is available today for UK and US customers.
Psoriasis is a chronic disease caused by an overactive immune system that accelerates the growth of skin cells. This affects approximately 125 million people worldwide and manifests as itchy, scaly, red skin on any part of the body. AxisBiotix-Ps â„¢ is a natural blend of bacteria specifically selected to relieve these symptoms by reducing inflammation in psoriatic patients. If left untreated, this inflammation could lead to more serious health problems, including psoriatic arthritis, as well as impacting an individual’s emotional and mental health, relationships, and more. Current treatments include topical creams, light therapy, as well as systemic prescription treatments, such as injections.
AxisBiotix-Ps was designed based on long-term scientific research into the role of the gut microbiome in our overall health, including the immune system. Researchers at SkinBioTherapeutics, the developer, have been studying the links between the gut microbiome and the skin for a decade. Unlike other probiotic supplements, the combination of four strains of probiotic bacteria contained in the product has been directly selected for psoriasis.
Earlier in 2021, the company concluded a customer study, in which participants who identified themselves as having psoriasis reported the positive effects of the dietary supplement. 76 percent of participants who completed the study noticed a reduction in itching and 73 percent reported less irritable skin. For the full report, please see HERE, and watch patient testimonials HERE.
AxisBiotix-Ps is sold in powder form and can be taken daily with cold liquids for best results. It is simple to incorporate into a daily routine and avoids worries about hard-to-reach places or issues about the right amount to apply, such as with topical creams. It does not contain steroids and is therefore suitable for long-term use.
Stuart Ashman, CEO of SkinBioTherapeutics, said:
“We are delighted that starting today, we can make AxisBiotix-Ps ™ available to everyone in the US and UK. Psoriasis can be an excruciating disease, and many suffer from it for decades. After years of scientific research, we now want to support the psoriatic community with a new approach to treating their symptoms, in the form of an over-the-counter dietary supplement that is easy to add to the daily routine. Our consumer study showed great results in reducing redness, itching, and scaling in the majority of our participants, and we hope many more will find relief using our product.
“We recognize that it may take a few weeks to notice the first changes, which is why we are providing two boxes for the price of one on all first orders for a limited time. “
AxisBiotix-Ps is available on the SkinBioTherapeutics online store by subscription at https://axis-biotix.myshopify.com, with priority to people registered on the pre-registration list. There is no need for a prescription to purchase the product.
Its price per bag (including VAT and excluding shipping and customs duties) in the US at $ 2.00 and in the UK at £ 1.50. Recognizing that it can take 3-4 weeks for the benefits of AxisBiotix-P to kick in, customers will receive a second free box with their first purchase for a limited time. The product is sold in boxes containing 28 sachets with customers subscribing on a 4 week or 8 week basis.
High resolution images of AxisBiotix-Ps â„¢ are available on request.
-Ends-
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The company’s proprietary technology platform, SkinBiotix®, is based on the discoveries made by Professor Catherine O’Neill and Professor Andrew McBain.
The Company targets a number of skin health sectors, the most advanced of which are cosmetic care and dietary supplements to modulate the immune system by harnessing the gut-skin axis. In each area, SkinBioTherapeutics plans to illustrate its technology with human studies.
The company was listed on AIM in April 2017 and is headquartered in Manchester, UK. For more information visit: www.skinbiotix.com.
[ad_2]
